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Abstract
Background: Publicly funded clinical trials require a substantial commitment of time and money.
To ensure that sufficient numbers of patients are recruited it is essential that they address
important questions in a rigorous manner and are managed well, adopting effective marketing
strategies.
Methods: Using methods of analysis drawn from management studies, this paper presents a
structured assessment framework or reference model, derived from a case analysis of the MRC's
CRASH trial, of 12 factors that may affect the success of the marketing and sales activities
associated with clinical trials.
Results: The case study demonstrates that trials need various categories of people to buy in –
hence, to be successful, trialists must embrace marketing strategies to some extent.
Conclusion: The performance of future clinical trials could be enhanced if trialists routinely
considered these factors.
Background
Results from randomised controlled trials (RCTs) make
an important contribution to improving patient care.
Some trials recruit a large number of patients and involve
the collaboration of many doctors, nurses and other
healthcare workers around the world. Because trials (espe-
cially large trials) can involve a substantial commitment
of time and money, it is essential that they address impor-
tant questions and use rigorous scientific methods. More
recently, however, it has been recognised that good man-
agement and effective marketing are also essential to ena-
ble sufficient numbers of participating centres and
patients to be recruited so that the study has enough sta-
tistical power [1]. This paper reports a case study of a
novel application of a marketing approach from the world
of business to a single clinical trial in order to develop a
reference model for use in other trials.
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Orientating concepts
Businesses strive to find customers and encourage them to
buy what is on offer. Clinical trials strive to find doctors
and patients and encourage them to sign up. Thus they
face similar challenges and may need to adopt similar
approaches to achieve their goals.
Clinical trials progress through distinctive stages, includ-
ing study design, obtaining funding, finding participants,
collecting and processing data, interpreting the results,
and reporting. In some stages of a trial the key require-
ment is to do good science. However, in others the chal-
lenge is quite different – the key requirement is to install
and operate a range of effective management techniques,
similar to those required for marketing a product. Indeed,
an experienced trialist observed that a trial is one fifth
structure (science) and four-fifths process (i.e. manage-
ment).
Marketing – the process of finding, winning over and
retaining customers – is an important topic in manage-
ment studies. Marketing has distinctive frameworks,
methods and techniques – generally drawn from sociol-
ogy and social psychology. Marketing became better
understood in the 1960s [2] and now the discipline is
ubiquitous within larger companies and many not-for-
profit organisations. A definition of marketing by McDon-
ald and Wilson [3] describes it as "a process for defining
markets, quantifying the needs of the customer groups
(segments) within these markets, determining the value
propositions to meet these needs, communicating these
value propositions to all those people in the organisation
responsible for delivering them and getting their buy-in to
their role, playing an appropriate part in delivering these
value propositions to the chosen market segments (and)
monitoring the value actually delivered" (pp11). (A value
proposition can be defined as a clear statement of the tan-
gible results a customer gets from using the products or
services).
The marketing dimension is included only tangentially in
the literature on clinical trials [1]. For example, trials are
generally stated to need recruitment strategies, use of
media and data tracking systems. However, the notion of
a developing and working to achieve a formal marketing
plan that covers all of the areas in the McDonald and Wil-
son definition is generally absent from descriptions of
trial management.
This is not to suggest that trial managers consider the topic
of marketing their trials to potential recruits lightly.
Indeed, it is a dominant concern for many trialists. For
example, the Diabetic Retinopathy Awareness Program
study [4] undertook many initiatives to recruit volunteers
and concluded, "these experiences substantiate the need
for a comprehensive coordinated approach, using
planned sources, to achieve recruitment success" (pp432).
Farrell [5] has argued persuasively that it is lack of solu-
tions to managerial issues that reduce the effectiveness of
trials, and Rowe [6] suggested that, "to get patients into
trials more efficiently pharma companies must begin to
think like marketers".
It can be argued that marketing is especially important in
clinical trials. Participation in a trial is a formal voluntary
act, in that participants need to abide by a set of rules.
Accordingly, not only is it necessary for people to volun-
teer, they also need to sign-up to behave in accordance
with a set procedure [7]. In short, participants in a trial (be
they clinicians or patients or their families) need to make
a commitment, and undertake additional work, often
without direct financial benefit to themselves.
From a marketing perspective, conducting a successful
trial can be seen as a process with five main stages (Figure
1). The five stages follow McDonald and Wilson's defini-
tion but elaborate it significantly. The purposes and con-
tent of each stage is amplified in Table 1.
Clinical trials require strategy, management, marketing
and sales. Undoubtedly they undertake the activities listed
in the table 1 in some way. However, what happens if
those who define the strategy of a trial, establish its man-
agement processes, devise its marketing plan and attempt
to sell the benefits of participation try to improve their
practice by explicitly engaging with the discipline of man-
Five stages in marketing a trialigure 1
Five stages in marketing a trial.
SET-UP
Gaining Prestige 
and Building 
Robust Systems
MARKET PLANNING
Segmenting Markets 
and Devising The 
Marketing Story
SIGNALING
Conveying The 
Message and Enrolling 
Patrons and Sponsors
LEARNING
Developing Market 
Knowledge and 
Redirecting Strategy
REINFORCING
Maintaining and 
Renewing
Commitment
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agement? The study described below provides some pre-
liminary answers to this question.
Methods
This study is a component of a three-part project – STEPS
(Strategies for Trials Enrolment and Participation) [8].
The first part included a quantitative analysis of the asso-
ciation between different patterns of recruitment in trials
and factors thought likely to influence this pattern, based
on an examination of Medical Research Council (MRC)
and Health Technology Assessment (HTA) records [9].
This showed recruitment often fails to meet targets. The
second part explored these issues further using qualitative
analysis of transcripts from semi-structured interviews
with key players in four trials considered by MRC/HTA as
exemplars [10], with a particular focus on the complexity
of financial negotiations. Here we report the third part
based on an in-depth investigation of a single trial from a
business perspective to assess its marketing strategy, in
order to develop a reference model to aid future trials.
The Corticosteroid Randomisation after Significant Head
injury (CRASH) trial [11] was a large scale RCT of the
effect of corticosteroids compared to placebo in improv-
ing important health outcomes [12]. The trial aimed to
recruit 20,000 head injured patients from hospitals world-
wide. As the trial participants were unconscious the mar-
keting strategy needed to focus on staff at participating
hospitals (and not on the patients).
CRASH had a marketing challenge since it needed to
engage the interest and collaboration of hundreds of peo-
ple internationally, including members of ethics commit-
tees, surgeons, doctors, nurses and administrators. During
the recruitment phase, one of us (DLF), a marketing and
strategy specialist from the academic business sector, was
invited to examine the trial as if it were a business, to com-
ment on its marketing strategy and to help the trial team
to understand and put in place a marketing plan over a
two-year period. He was given access to all trial docu-
ments (apart from confidential investigators' personal
details and patient data). He visited three participating
hospitals in England, observed training sessions and inter-
viewed or facilitated group discussions with doctors,
nurses and ancillary staff. He also conducted 11 inter-
views, and held numerous meetings with members of the
trial management team.
The methodological approach used techniques drawn
from adaptive theory [13], case analysis [14] and action
research [13]. The researcher's interview notes were ana-
lysed using a grounded theory framework [15] and the
emerging model was compared with data from studies in
commercial enterprises. The N-Vivo qualitative analysis
software program was used to structure data initially but
manual analytic methods were used later as often the pur-
pose was to highlight what participating agents were not
saying – rather than what they were saying. A professor of
management (independent of the study team) checked
the interpretative framework against the raw data. Emerg-
ing results were presented to a peer group (the STEPS
research team) and to the team members of the CRASH
trial. A one-day marketing workshop using an action
research approach was held with the trial team to provide
Table 1: Activities within the five stages in marketing a trial
Stage Marketing Purposes
Set-Up 1. To gain the buy-in of the necessary authorities and stakeholders.
2. To gain the buy-in of opinion leaders whose explicit approval provides legitimacy and prestige for the trial.
3. To construct a marketing function within the trial and devise robust systems for ensuring that the marketing (and later 
sales) activities are undertaken efficiently, effectively and in accordance with the values and goals of the trial.
Market Planning 1. To identify and describe the distinctive features of the 'segments' of the 'market' to be targeted.
2. To discover what people in each of the selected market segments value (i.e. what would encourage them to 'sign-up').
3. To develop a 'value proposition' (or more than one if required) that can be tested with each of the targeted segments.
4. To enrol the whole trial organisation in working within the trial's 'marketing brief'.
Signalling 1. To convey, fully and persuasively, the 'value proposition' to sufficient numbers of people in the target market.
2. To convey, fully and persuasively, the 'value proposition' to intermediaries (e.g. doctors or nurses), influencing bodies (e.g. 
ethics committees) and other agents that can either help or hinder the conduct of the trial.
Learning 1. To learn, through doing, about 'the market'.
2. To utilise ongoing learning to develop more effective policies and practices.
3. To evaluate, and redirect the strategy of a trial as learning is acquired.
Reinforcing 1. To maintain momentum by renewing or upgrading 'the offer' made to participants.
2. To sustain commitment of interested parties and other agencies whose support will be needed.
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insights into the extent to which concepts and practices
from the business world [15] might have relevance to
management of clinical trials. Early in 2004 an additional
five-hour workshop was held with representatives from
three trials (one of which was the CRASH trial) to gain fur-
ther insight into the practical implications of the findings,
providing a further opportunity to validate the
researcher's theory building process.
As the approach reported in this paper was part of a strat-
egy to try to improve recruitment into the CRASH trial, the
STEPS investigators decided that separate ethics commit-
tee approval would not be required for this process as the
CRASH trial had already received approval from the North
London MREC.
Results
When commercial companies sell a product they attempt
to convince a potential customer that they will gain bene-
fits directly from their purchase. In the CRASH the trial
managers were seeking to gain a commitment to engage
from clinical professionals who would make no material
gain for themselves. Accordingly, the CRASH trial was sell-
ing an opportunity for clinical professionals to participate
in improving future clinical practice – an activity that can
be seen as being akin to a charitable endeavour [7]. A chal-
lenge for the CRASH trial was to promote the idea that if
a clinician signed up to the trial then medicine itself
would progress and the clinician would be fulfilling a pro-
fessional obligation.
A previously unexplored dimension of the marketing
challenge was found to be the difficulty of gaining an evi-
dence-based understanding the reasons why participants
(in this case hospitals) signed up and what motivated
them to fulfil a commitment that had no sanctions for
non-performance. An analysis of feedback from partici-
pating hospitals concluded that they opted in for a variety
of reasons, including the perceived merits of the study, the
stature of the sponsors and advocates, the status provided
to participants through participation and the affordability
of participation (i.e how much time and effort would be
required).
A tentative reference model was developed from the
research date that facilitated an ongoing assessment of the
sales and marketing capability of the trial.
The reference model
The reference model defines the capabilities required for
successful marketing and selling of a medical trial that
offered a holistic ideal type that the trial could use to
define excellence [17]. It has four domains and 12 compo-
nents and is illustrated as a wheel diagram (Figure 2). The
twelve components are described below.
Ia) Developing brand values
Brand values define what a brand is and what it is not –
i.e. its personality. A clinical trial can be seen as a brand.
Without explicit brand values it is impossible to commu-
nicate a coherent and persuasive perception of a trial's
promise – i.e. what the trial intends to deliver to medicine,
doctors, patients etc.
Ib) Gaining legitimacy and prestige
Trials need legitimacy – they need to be positively tagged
by association with prestigious individuals and institu-
tions (so a hospital doctor may say, "I know that this is an
important trial because Professor X, who I know and
respect, is supporting it). Legitimacy and prestige provide
persuasive credibility key to gaining access to decision-
makers who decide whether a trial should be supported
and maintain engagement.
Ic) Signalling worthiness
It is vital to signal to likely participants that, "this trial will
create greater value than the costs (time, effort or money)
involved". Buy-in is more likely to occur when partici-
pants realise, and identify with, the potential benefits that
will be delivered by the success of the trial. Methods for
doing this include presentations at conferences, journal
publications, advertising, public relations and training
materials.
Reference modelFigure 2
Reference model.
MAKING THE
SALE
BUILDING
BRAND VALUES
I
IIIII
IV
IIc Adopting An
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Plan
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IIb Devising
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IVb Providing
Frequent Positive
Reinforcement
IIa Providing
Simple,
Complete
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IIIb Delivering A
Multi-Audience,
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Message
IIIc Achieving Buy-
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IIa) Providing simple, complete processes
Trials require participants to undertake work that is addi-
tional to their normal duties. Providing simple, complete
processes reduces the costs of participation and increases
the chances that involvement will be affordable.
IIb) Devising strategies for overcoming resistance
Potential participants frequently raise objections. Trials
should have standard and persuasive answers to these.
Having a persuasive answer for each objection increases
the probability of making a sale.
IIc) Adopting an explicit marketing plan
The marketing of a trial is too important and too compli-
cated to be done informally. A formal marketing plan is
required that should include a definition of target market
segments (groups that need to buy in to the trial) and the
trial's unique selling points (USPs). It is to be expected
that the marketing plan will need to be revised frequently
– probably every quarter. It can be useful to have separate
plans for dealing with (1) The Uninformed (Inform and
persuade with targeted stories), (2) The Unconvinced
(Address concerns point-by-point – "get to yes"), (3) The
Laggards (Enrol, cajole, facilitate and target), (4) The
Steady Performers (Reward, renew, upgrade and recognise)
and (5) The Stars (Honour, learn from, and nourish).
IIIa) Engaging active sponsors, champions and change agents
Selling a trial to prospective participants requires persua-
sion. This requires enrolling sponsors (public advocates),
champions (activists) and change agents (facilitators).
Trial managers need a network of supporters to spread the
message. Persuasion is more likely to occur if the advocate
is respected and known personally to the prospective par-
ticipant.
IIIb) Delivering a multi-audience, multi-level message
Trials need to convey sales messages through publicity,
presentations, training materials, etc. These should be
tuned to the distinctive needs of target groups – for exam-
ple, surgeons are likely to be persuaded by different mes-
sages than administrators or nursing staff. Speaking in the
language of the person being targeted and addressing their
particular pattern of motivation is more likely to succeed
than a one size fits all approach.
IIIc) Achieving buy-in (in public)
Public buy-in requires that intended participants
announce their commitment to join the trial in a setting
where others hear them. This is important because when
someone states, in public, that they are willing to under-
take an action, then they are more likely to abide by their
commitment than if they take a silent decision – that can
be forgotten easily.
IVa) Ensuring positive moments of truth
People evaluate organisations (including trial manage-
ment teams) on the basis of their experiences at moments
of truth. For example, if a doctor has a technical question
about entering a patient into a trial she will gain a strong
impression of the trial management team's competence
by the way that the query is handled. If trialists behave
well in a moment of truth then loyalty grows; if not, loy-
alty diminishes.
IVb) Providing frequent positive reinforcement
Positive reinforcement for existing participants should be
an important part of a trial's participant retention strategy.
It is more expensive to recruit new participants than to
retain existing participants.
IVc) Facilitating incorporation into routines
Activities that become embedded as routines are more
likely to be done than one-offs. Trial procedures should be
incorporated into the routines of units undertaking the
work.
Discussion
We found that the CRASH trial faced challenges in mar-
keting and selling that were mission critical – i.e. if goals
were not achieved then the trial would fail. Farrell,
amongst others, has been arguing for a greater recognition
of the role of management in the conduct of clinical trials
[5]. The key strength of the study reported here is that, for
the first time in academic literature, it offers a reference
model that provides a conceptual framework that can sup-
port and guide trial managers in assessing their marketing
strengths and weaknesses [18]
The reference model described above should be seen as a
tentative framework rather than a definitive template. It
was developed from a theory-building process from a sin-
gle trial and is best considered as a set of provocative
hypotheses – later they may be developed as provisional
audit tools. It may be that the reference model could be
used as a diagnostic tool to identify if, and at what points,
a trial is failing so that remedial interventions could be
undertaken. An audit of the CRASH trial enabled compo-
nents that were considered to be weaker than others to be
identified and initiatives undertaken to improve in these
areas. Further research is needed in other trials to explore
whether the model is complete and correct and whether
useful audit tools can be developed.
Clinical trials are not only research activities- they are also
time-bound businesses that have two interdependent sets
of processes – one clinical and the other managerial. In
the main, since trials are seen as clinical endeavours, they
are dominated by clinical issues and led by people with
clinical skills. This is essential for certain policies and
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practices but this cultural bias can result in the managerial
aspects of trials being, relatively, neglected. If this is true,
even if only in part, it means that the radical improvement
of clinical trials could require different ways of defining
the challenges of running successful trials – in particular,
to ensure that they are seen as management challenges
that can benefit from the informed use of selected man-
agement processes and techniques.
These considerations suggest that looking within past tri-
als for the answers to the problem of under-performing
trials is necessary but will not be sufficient. In order to
improve trials it will be necessary to look outside the
world of clinical practice, into the worlds of business strat-
egy, management, marketing and sales to gain a fuller
understanding of what can be done to upgrade perform-
ance of clinical trials. This insight is not new. Donovan,
Mills et al [19] state that the, "methodological literature
(on trials) is almost exclusively statistical and epidemio-
logical, and very little of it is concerned with the conduct
or the particular demands that trials put on trialists and
participants" (pp766).
Conclusion
This study could begin to change the ways that trial man-
agers undertake their work. Also, it provides a different
way to think about the skill sets and competencies needed
by those who manage clinical trials. In essence, the mes-
sage of this study is simple – even simplistic. It is that trials
are both complex projects and businesses (they need to
find customers). The key implication for clinicians is that
insufficient attention to management issues and market-
ing or sales activities will degrade the performance of the
trial.
There are significant implications for policy makers and
funding bodies as well. If the tentative conclusions of this
study are correct, then the funders will need to examine
more than the scientific case before sponsoring a trial.
They will need to see a marketing and sales plan, and be
assured that all of the required elements of the business
system will be developed. Since a successful trial requires
both good science and good management, both need to
be given their due weight.
But there are differences. Business is about profit. Medi-
cine is driven by human values. It would be wrong to infer
that publicly funded trials need to be more like businesses
– rather, we suggest, that trials may benefit from using
business concepts and business techniques.
This cross-disciplinary study was based on the premise
that something new would be gained if a researcher from
the world of business and management studied a clinical
trial from his disciplinary perspective and worked with tri-
alists to devise a useful framework. Since innovation is fre-
quently facilitated by a clash of disciplines, it may be
some of the insights needed to improve trial recruitment
will come from fields other than medicine.
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